Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

HemaSphere·2026
Same author

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors.

The Lancet. Haematology·2025
Same author

Opioid substitution treatment, relapse and addiction-related outcomes in prison setting and after release: A longitudinal study.

Nordisk alkohol- & narkotikatidskrift : NAT·2024
Same author

Study protocol for a multicentre randomised controlled trial evaluating the efficacy of an online yoga intervention in high-grade glioma patients and their caregivers: the YINOTA-O-trial.

BMJ open·2024
Same author

Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment.

Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie·2024
Same author

Role and benefits of infectious diseases specialists in the COVID-19 pandemic: Multilevel analysis of care provision in German hospitals using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) cohort.

Infection·2024

Related Experiment Video

Updated: Feb 10, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.6K

[Thrombotic Microangiopathies].

Jörg Schubert1, Michael Dechant2

  • 1Chefarzt der Klinik für Innere Medizin II am Elblandklinikum Riesa.

Deutsche Medizinische Wochenschrift (1946)
|May 29, 2018
PubMed
Summary
This summary is machine-generated.

New therapies offer hope for thrombotic microangiopathies (TMA), a group of deadly blood disorders. Targeted treatments like Eculizumab and Caplacizumab are improving patient outcomes and reducing mortality.

More Related Videos

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

1.1K
Intravital Microscopy and Thrombus Induction in the Earlobe of a Hairless Mouse
09:01

Intravital Microscopy and Thrombus Induction in the Earlobe of a Hairless Mouse

Published on: April 2, 2017

10.2K

Related Experiment Videos

Last Updated: Feb 10, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.6K
Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
05:44

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins

Published on: May 24, 2024

1.1K
Intravital Microscopy and Thrombus Induction in the Earlobe of a Hairless Mouse
09:01

Intravital Microscopy and Thrombus Induction in the Earlobe of a Hairless Mouse

Published on: April 2, 2017

10.2K

Area of Science:

  • Hematology
  • Internal Medicine

Background:

  • Thrombotic microangiopathies (TMA) are severe, often fatal, hematological disorders.
  • Historically, plasmapheresis was the primary treatment, with limited options for distinct TMA subtypes.
  • Recent advancements have introduced novel targeted therapies for various TMAs.

Purpose of the Study:

  • To review the evolving therapeutic landscape for thrombotic microangiopathies.
  • To highlight the efficacy of newly approved and investigational drugs.
  • To emphasize the need for precise diagnostics to guide targeted TMA treatment.

Main Methods:

  • Review of current literature on TMA pathogenesis and treatment.
  • Analysis of clinical trial data for novel therapeutic agents.
  • Discussion of diagnostic strategies for differentiating TMA entities.

Main Results:

  • Eculizumab demonstrates efficacy in atypical hemolytic uremic syndrome (aHUS).
  • Caplacizumab significantly improves remission rates and reduces mortality in TTP.
  • Defibrotide shows improved outcomes for therapy-associated TMA (VOD/SOS).

Conclusions:

  • The treatment of TMAs has significantly advanced beyond plasmapheresis.
  • Targeted therapies offer improved prognoses for patients with specific TMA subtypes.
  • Individualized diagnostics are crucial for selecting appropriate, life-saving TMA treatments.